LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study.
D. Bilton, G. Tino, A. Barker, D. Chambers, A. De Soyza, L. Dupont, C. O'Dochartaigh, E. van Haren, L. Otero Vidal, T. Welte, H. Fox, J. Wu, B. Charlton (London, Newcastle-upon-Tyne, United Kingdom; Philadelphia, Portland, United States Of America; Brisbane, Sydney, Australia; Leuven, Belgium; Auckland, New Zealand; Heerlen, Netherlands; Partido de Vicente Lopez, Argentina; Hannover, Germany)
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Bilton, G. Tino, A. Barker, D. Chambers, A. De Soyza, L. Dupont, C. O'Dochartaigh, E. van Haren, L. Otero Vidal, T. Welte, H. Fox, J. Wu, B. Charlton (London, Newcastle-upon-Tyne, United Kingdom; Philadelphia, Portland, United States Of America; Brisbane, Sydney, Australia; Leuven, Belgium; Auckland, New Zealand; Heerlen, Netherlands; Partido de Vicente Lopez, Argentina; Hannover, Germany). LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study.. Eur Respir J 2013; 42: Suppl. 57, 1966
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Inhaled mannitol for non-cystic fibrosis bronchiectasis - results of a 12 month, multi-centre, double-blind, controlled study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014
LATE-BREAKING ABSTRACT: Treating the most diseased segments in patients with severe emphysema: 6 month results from the STEP-UP randomized controlled trial (RCT) Source: International Congress 2015 – Advances in therapeutic bronchoscopy Year: 2015
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Source: Eur Respir J 2002; 20: 245 Year: 2002
STEP-UP randomized controlled trial of vapor ablation in patients with severe emphysema: 12 month results Source: International Congress 2016 – Endoscopic lung volume reduction I Year: 2016
Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
LATE-BREAKING ABSTRACT: COPD-associated severe pulmonary hypertension (COPDPH): results of a 16-weeks prospective multicenter, double-blind, placebo-controlled randomized clinical trial (RCT) [SPHERIC-1 (http://clinicaltrials.gov/ct2/show/NCT01441934)] investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013
Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007
Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial Source: International Congress 2014 – Sarcoidosis Year: 2014
LATE-BREAKING ABSTRACT: Simtuzumab in idiopathic pulmonary fibrosis: Results of a randomized clinical trial Source: International Congress 2016 – IPF treatment I Year: 2016
Exercise training is beneficial in patients with non-cystic fibrosis bronchiectasis – A multi-centre, randomised controlled trial Source: Annual Congress 2012 - Exercise and physical activity: towards evidence-based benefits in different populations Year: 2012
Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON) Source: International Congress 2015 – Treatment of IPF Year: 2015
LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial. Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020
LATE-BREAKING ABSTRACT: Randomised, double blind, placebo-controlled phase III study of inhaled dry powder mannitol in cystic fibrosis (CF) Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018
Patients’ adherence to chronic treatment in lung diseases: Preliminary data from a randomized controlled trial Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016